🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Recurrent Nasopharyngeal Carcinoma

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma NCT04778956Phase 37 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Sun Yat-sen University · Tests: Toripalimab, salvage surgery EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma NCT06802835Phase 1, Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin, IMRT Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma NCT04425265NA3 sites📍 Guangzhou📍 Zhuhai📍 Nanchang Sun Yat-sen University · Tests: Plasma radiofrequency ablation, Electrocautery block resection PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC NCT07332247Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Selective re-irradiation, Immediate re-irradiation PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients NCT03907826Phase 312 sites📍 Guangzhou📍 Beijing📍 Chengdu Sun Yat-sen University · Tests: PD-1 blocking antibody, GP, IMRT TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer NCT06868433Phase 12 sites📍 Atlanta📍 Atlanta Emory University · Tests: Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Res… Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial NCT05340491Phase 312 sites📍 Guangzhou📍 Beijing📍 Chengdu Sun Yat-sen University · Tests: Toripalimab, Chemotherapy, Intensity modulated radiotherapy Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC NCT06197776n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: cisplatin-based chemoradiotherapy combined with immunotherapy LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC NCT07325539Phase 22 sites📍 Guangzhou📍 Shenzhen Sun Yat-sen University · Tests: Gemcitabine(GEM), Cisplatin, Toripalimab, LDRT Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC NCT05854849Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Camrelizumab, Gemcitabine, Cisplatin, Apatinib Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II) NCT07277764Phase 21 site📍 Nanchang Jiangxi Provincial Cancer Hospital · Tests: High-Low Dose Radiotherapy Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial NCT07070479Phase 26 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Ming-Yuan Chen · Tests: Ivonescimab, Nimotuzumab, Irinotecan liposome, S-1, Mitoxantrone Hydrochloride Liposome Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial NCT07101744Phase 21 site📍 Guangdong Sun Yat-sen University · Tests: Iparomlimab and Tuvonralimab TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma NCT06912711Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Toripalimab, Nimotuzumab, surgery Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors NCT07625423Phase 11 site📍 Chengdu West China Hospital · Tests: EDS01 1.0×10^11 VP + Toripalimab, EDS01 5.0×10^11 VP + Toripalimab, EDS01 1.0×10^12 VP + Toripalimab Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma NCT06509009Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Nimotuzumab Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC NCT06177301Phase 31 site📍 Shanghai Fudan University · Tests: Tislelizumab combined with GX, Tislelizumab combined with GP Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation NCT06662058NA1 site📍 Atlanta Emory University · Tests: Audiometric Test, Audiometric Test, Audiometric Test, Interview Deep Learning-based sbORN Diagnostic Model NCT06463392n/a1 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: No Intervention: Observational Cohort Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer NCT06980038Phase 212 sites📍 Irvine📍 Los Angeles📍 Los Angeles National Cancer Institute (NCI) · Tests: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection, Cemiplimab, Computed Tomograp… SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy NCT06676722Phase 22 sites📍 Xiamen📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: SBRT combined with Nimotuzumab followed by Tislelizumab Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants NCT00898638n/a4 sites📍 Nashville📍 Nashville📍 Nashville Vanderbilt University Medical Center · Tests: biologic sample preservation procedure, medical chart review Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma. NCT07781358Phase 21 site📍 Shanghai Hongmeng Yu · Tests: Becotatug Vedotin, PD-1 / PD-L1 monoclonal antibody Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC NCT06657690Phase 21 site📍 Zhuhai Sun Yat-sen University · Tests: Irinotecan liposome, S-1 Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer NCT06029270Phase 295 sites📍 Dublin📍 Fremont📍 Fresno National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Scan, Carboplatin, Cisplatin, Computed Tomography A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. NCT07258979Phase 1, Phase 220 sites📍 Chongqing📍 Fuzhou📍 Xiamen MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL201, Toripalimab, Cisplatin JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma NCT07690787Phase 21 site📍 Hong Kong Chinese University of Hong Kong · Tests: JS207, Paclitaxel, Capecitabine A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy NCT06839066Phase 215 sites📍 Fuzhou📍 Dongguan📍 Guangzhou Shanghai Henlius Biotech · Tests: HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy